Clinical and Epidemiological Findings on Pediatric Rheumatism

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: closed (30 August 2024) | Viewed by 1743

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pediatrics, National and Kapodistrian University of Athens, "ATTIKON" General Hospital, Athens, Greece
Interests: pediatric rheumatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pediatric rheumatic conditions encompass a range of autoimmune and inflammatory disorders that can significantly affect a child's health and well-being. Conditions such as juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, and related disorders require a comprehensive understanding of their clinical presentations, disease course, and epidemiological patterns.

This Special Issue provides an opportunity for researchers to contribute their latest insights and discoveries in the field of pediatric rheumatology. Key areas of interest include clinical observations detailing disease presentations, disease-modifying therapies, long-term outcomes, and innovative treatment strategies. Epidemiological investigations shedding light on prevalence, risk factors, and disease trends are also crucial for informing public health efforts.

The aim of this Special Issue is to foster collaboration and knowledge exchange among researchers working on pediatric rheumatism, enabling a deeper understanding of disease complexity and variability. By showcasing current research and sharing valuable clinical experiences, we aim to advance our comprehension of pediatric rheumatism and its impact on affected children and their families.

Dr. Lampros Fotis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric rheumatology
  • clinical presentations
  • epidemiology
  • disease-modifying therapies
  • long-term outcomes
  • treatment approaches
  • autoimmune disorders
  • inflammatory conditions
  • juvenile idiopathic arthritis
  • systemic lupus erythematosus
  • juvenile dermatomyositis
  • childhood rheumatic diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3459 KiB  
Article
Treatment Patterns in Polyarticular Juvenile Idiopathic Arthritis: A Retrospective Observational Health Claims Data Study
by Gerd Horneff, Julia Borchert, Joanna Diesing, Pascal Klaus, Ria Heinrich, Heike Dally, Christine Hagemann, Simon Kock and Tonio Schönfelder
Life 2024, 14(6), 712; https://doi.org/10.3390/life14060712 - 31 May 2024
Viewed by 1343
Abstract
(1) Background: Achieving inactive disease decreases long-term joint damage in patients with polyarticular juvenile idiopathic arthritis (polyJIA). The aim of our study was to describe average time to treatment and medication changes over time. (2) Methods: Incident polyJIA patients were retrospectively identified in [...] Read more.
(1) Background: Achieving inactive disease decreases long-term joint damage in patients with polyarticular juvenile idiopathic arthritis (polyJIA). The aim of our study was to describe average time to treatment and medication changes over time. (2) Methods: Incident polyJIA patients were retrospectively identified in the InGef and WIG2 longitudinal health claims databases. Drug escalation level changes were evaluated longitudinally and cross-sectionally across three years, as follows: no treatment, glucocorticoids (GCs) and/or non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and biological disease-modifying antirheumatic drugs (bDMARDs). (3) Results: On average, newly diagnosed polyJIA patients received their first csDMARD prescription after 128 days and their first bDMARD prescription after 327 days. More patients were treated with csDMARDs than with bDMARDs at diagnosis; however, 24% and 12% (InGef and WIG2 databases, respectively) had no JIA treatment. After three years, 45% and 31% were not taking any treatments, while 18% and 36% were prescribed bDMARDs. Among patients initiating bDMARDs, most continued treatment for three years, with some switching to csDMARDs or discontinuing treatment. Patients treated only with csDMARDs took them longer, compared to those additionally taking other DMARDs. Patients treated with bDMARDs took them about twice as long as the csDMARDs they took prior. (4) Conclusion: A substantial number of patients with polyJIA are not treated as intensively as guidelines recommend. Full article
(This article belongs to the Special Issue Clinical and Epidemiological Findings on Pediatric Rheumatism)
Show Figures

Figure 1

Back to TopTop